

**The Role of Polycomb Repressive
Complex 2 and Effects of Lobarstin in
Glioblastoma Multiforme**

SOJIN KIM

The Graduate School

Yonsei University

Department of Biomedical

Laboratory Science

The Role of Polycomb Repressive Complex 2 and Effects of Lobarstin in Glioblastoma Multiforme

**A Dissertation Submitted to the Department of Biomedical
Laboratory Science and the Graduate School of Yonsei
University in partial fulfillment of the requirements for the
degree of Doctor of Philosophy**

So Jin Kim

December 2013

**This certifies that the dissertation of So Jin Kim is
approved.**

Thesis Supervisor: Tae Ue Kim

Hyeyoung Lee : Thesis Committee Member

Yong Serk Park : Thesis Committee Member

Yoon Suk Kim: Thesis Committee Member

Heekyoung Chung: Thesis Committee Member

The Graduate School

Yonsei University

December 2013

CONTENTS

LIST OF FIGURES	V
ABBREVIATIONS	VII
ABSTRACT	VIII
I. INTRODUCTION	1
II. MATERIALS AND METHODS	9
1. Cell cultures	9
2. Reagents	9
3. Plasmid preparation and transfection	
3-1. Cloning short hairpin RNA into lenti-viral vector	10
3-2. Transfection of lenti-viral vector and transduction of lenti-virus	10
3-3. Cloning short hairpin RNA into retro-viral vector	11
3-4. Transfection of retro-viral vector and transduction of retro-virus	11
4. Cell viability assay	12

5. Cell cycle analysis	12
6. Reverse transcription-polymerase chain reaction (RT-PCR)	
6-1. Isolation of total RNA	13
6-2. cDNA synthesis and RT-PCR	14
7. Western blot analysis	15
8. Immunostaining	16
9. Alkaline comet assay	17

III. RESULTS

1. PRC2 enhances cell proliferation via modulation of the MYC-SKP2-CDKN1B axis in glioblastoma

1-1. PRC2 expression is up-regulated in T98G glioblastoma cells	19
1-2. PRC2-depletion inhibits cell proliferation of GBM cells	21
1-3. PRC2-depletion attenuates cell cycle progression at G ₁ phase	24
1-4. PRC2-depletion stabilizes and enhances nuclear accumulation of CDKN1B protein	26
1-5. PRC2-depletion represses MYC-dependent SKP2 expression	

-----	31
1-6. Comparison of the expression of EZH2, MYC and CDKN1B proteins between human glioblastoma samples and normal brain samples -----	39
2. PRC2-depletion increases chemosensitivity of drug-resistant human glioblastoma cells by repressing DNA repair system	
2-1. PRC2-depletion enhances sensitivity for chemotherapeutic agents -----	42
2-2. Potentiation of temozolomide by PRC2-depletion is associated with reduced DNA damage recovery -----	45
2-3. PRC2-depletion down-regulates the expression level of DNA repair genes	48
2-4. Comparison of the expression levels of EZH2, MGMT, and PARP1 proteins between human glioblastoma samples and normal brain samples -----	51
3. Lobarstin enhances chemosensitivity in human glioblastoma T98G cells	
3-1. Lobarstin inhibits the cell viability of glioblastoma cell -----	55
3-2. Co-treatment with lobarstin and TMZ enhances cytotoxicity -----	57
3-3. Lobarstin reduces TMZ-induced DNA damage and recovery -----	60
3-4. Lobarstin down-regulates DNA repair genes -----	64

IV. DISSCUSSION	-----68
V. REFERENCES	-----75
ABSTRACT IN KOREAN	-----101

LIST OF FIGURES

Figure 1. Expression of Polycomb group genes in human Glioblastoma cell lines -----	20
Figure 2. PRC2-depletion inhibits the proliferation of T98G glioblastoma cell ---	23
Figure 3. PRC2-depletion attenuates cell cycle progression at G ₁ phase of glioblastoma cells -----	25
Figure 4. PRC2-depletion stabilizes and enhances nuclear accumulation of CDKN1B protein -----	30
Figure 5. PRC2-depletion represses SKP2 expression -----	35
Figure 6. PRC2-depletion down-regulates MYC-dependent SKP2 expression ----	36
Figure 7. PRC2-depletion alters the expression of MYC-SKP2-CDKN1B axis in T98G cells -----	38
Figure 8. Comparison of the expression levels of selected proteins between human glioblastoma and normal brain samples -----	40
Figure 9. Hypothetical figure representation of PRC2 regulating MYC-SKP2- CDKN1B axis in human glioblastoma cells -----	41
Figure 10. PRC2-depletion in T98G cells dramatically increases the sensitivity for chemotherapeutic agents -----	44
Figure 11. Potentiation of TMZ by PRC2-depletion is associated with reduced DNA	

damage recovery	-----47
Figure 12. PRC2-depletion in T98G cells inhibits the expression of DNA repair	
genes	-----49
Figure 13. PRC2-depletion inhibits PARP1 expression in nucleus	-----50
Figure 14. Comparison of the expression levels of EZH2, MGMT, and PARP1	
between human glioblastoma samples and normal brain samples	-----53
Figure 15. Hypothetical figure representation of PRC2 regulating Base excision	
repair in human glioblastoma cells	-----54
Figure 16. Chemical structure and cytotoxicity of Lobarstin	-----56
Figure 17. Lobarstin potentiates the sensitivity of TMZ in MGMT-positive T98G	
Cells	-----59
Figure 18. Effects of Lobarstin on DNA damage and recovery	-----63
Figure 19. Effects of Lobarstin on the expression of DNA repair associated genes	
-----	-----66
Figure 20. Hypothetical figure representation of Lobarstin regulating repair system	
in human glioblastoma cells	-----67

ABBREVIATIONS

BER : Base excision repair

EED : Embryonic ectoderm development

EZH : Enhancer of zeste homolog

GBM : Glioblastoma multiforme

H3K27me3 : Trimethylation on histone H3 at lysine 27

MGMT : O⁶-methylguanine-DNA methyltransferase

MMR : Mismatch repair

MPG : N-methylpurine-DNA-glycosylase

PcG : Polycomb group

PRC : Polycomb repressive complex

PTP1B : Protein tyrosine phosphatase 1B

RT-PCR : Reverse transcription-polymerase chain reaction

SUZ12 : Supporting proteins suppressor of zeste

TMZ : Temozolomide

ABSTRACT

Glioblastoma multiforme (GBM) is a grade IV primary malignant brain tumor. The elevated expression of polycomb repressive complex 2 (PRC2) proteins such as EZH2 and SUZ12 have been found in GBM and their expression levels often correlate with poor prognosis. In order to find anti-proliferative factors and to increase the potential of anti-cancer drug for glioblastoma treatment, I studied two different approaches. First, I tested that PRC2 may play as master regulator in GBM. Second, I investigated the influence of co-treatment with lobarstin and TMZ on chemosensitivity of glioblastoma cells. Upon knock-down of PRC2, cell growth was attenuated and cells were accumulated at G₁ phase of the cell cycle. Among several G₁ regulators, the total and nuclear CDKN1B protein levels were drastically up-regulated by PRC2 depletion. Interestingly, the expression of SKP2, a component of the SCF^{SKP2} E3 ubiquitin ligase which is known to promote the degradation of CDKN1B protein degradation was significantly reduced under depleted expression of PRC2. Furthermore, PRC2-depletion led to down-regulation of MYC expression at both mRNA and protein levels. In agreement with the *in vitro* results, glioblastoma patients with elevated EZH2 expression showed high MYC expression but reduced CDKN1B expression. Temozolomide (TMZ) has been used as standard therapy for glioblastoma patients, however, this treatment does not improve the prognosis and survival of patients because of rapid DNA repair system. Upon transient PRC2-depletion, TMZ-induced cytotoxicity and the DNA damage were

found to be extended. Interestingly, PRC2-depletion had no effect on MGMT expression, but the expressions of the base excision repair (BER) genes such as PARP1, XRCC1, and LIG3 were significantly decreased. In agreement with the *in vitro* results, glioblastoma patients with high EZH2 expression showed increased PARP1 expression level. In order to evaluate the possibility of developing combinatorial therapy for GBM, I tested the combination effect of lobarstin and TMZ on T98G cells. Co-treatment with lobarstin and TMZ resulted in enhanced cytotoxicity for GBM cells through repressing DNA-recovery. Expressions of DNA repair genes such as MGMT, PARP1 and LIG 3 were significantly reduced in lobarstin and TMZ co-treated cells. Taken together, these results showed that the PRC2-depletion enhances inhibitory effect on GBM growth and potentiates TMZ antitumor activity. In summary, the effects of PRC2 can be considered as a potential targets for developing a novel therapeutic approaches. Additionally, lobarstin can be used as a potential combination drugs with TMZ for efficient GBM therapy.

Keywords: glioblastoma, polycomb repressive complex 2, EZH2, SUZ12, lobarstin, temozolomide, DNA repair

I. INTRODUCTION

Glioblastoma arises from the malignant transformation of astrocytes, is a highly aggressive brain tumor [1, 2] and is classified into four different grades (I, II, III and IV) based on the degree of malignancy [3]. Glioblastoma multiforme (GBM) is classified as grade IV and is the most aggressive form of glioblastoma accompanied by extremely poor prognosis due to the fact that the most of the GBM patients die within 2 years from the diagnosis [4, 5]. GBM has the typical characteristics of rapid, uncontrolled cell proliferation, necrosis formation, evasion of apoptosis, elevated angiogenesis and microvascular proliferation [6, 7]. Malignancy of GBM results from several genetic abnormalities such as increased levels of epidermal growth factor receptor (*EGFR*) and platelet-derived growth factor receptor (*PDGFR*), disruptions of cell cycle regulation by *INK4a-ARF* abnormalities, mutations in the *TP53* tumor suppressor gene associated with *CDK4* amplification or *RB* loss [1, 6].

Currently, standard treatment for GBM consists of surgical resection, radiotherapy, concomitant and adjuvant with temozolomide (TMZ). However, the outcome are extremely poor [7] and these treatments result in several side effects that diminishes the quality of life of the patients. Among several chemotherapeutics, TMZ is the most widely used for the treatment of GBM and induces the cell death by generating a spectrum of methyl-adducts on DNA [8, 9]. The major site of TMZ-induced DNA methyl-adducts are N⁷-methylguanine (>70%), N³-methyladenine (9.2%), and O⁶-methylguanine (5%) [10-12]. The cytotoxicity of TMZ is mainly dependent on the

efficiency of DNA repair system. Improper DNA repair system results in DNA nick formation followed by cell apoptosis and cell death [13]. Although O⁶-methylguanine adduct is about 5%, which is considered as most toxic lesion and is directly repaired by O⁶-methylguanine methyltransferase (MGMT) and mismatch repair (MMR) [14].

Another important mechanism involved in resistance to TMZ therapy is a base excision repair (BER), which repairs N⁷-methylguanine and N³-methyladenine DNA adducts. BER is initiated by N-methyl-purine DNA glycosylase (MPG) which creates apurinic/apyrimidinic (AP) site through the N-glycosidic bond cleavage of deoxy-guanosine residues [15]. Next, AP endonuclease 1 (APE1) recognizes and cleaves an AP site to yield a 3'-hydroxyl group adjacent to a 5'-deoxyribose phosphate [15]. Poly (ADP-ribose) polymerase 1 (PARP1) acts as a DNA nick-sensor, binds to DNA damage sites, and catalyzes poly (ADP-ribosylation) the chromatin-associated protein including itself [16, 17]. X-ray repair cross-complementing protein 1 (XRCC1) has a tendency to interact with PARP1. Thus, XRCC1 acts as a scaffolding protein by directly binding to PARP1 and activates other BER components such as DNA polymerase beta (POL β) and DNA ligase III (LIG3) [18] which are involved in the DNA repair mechanism. In spite of N⁷-methylguanine and N³-methyladenine DNA adducts comprise most of the TMZ-induced DNA lesions, toxicity is relatively less due to rapid repair of these adducts by BER [9]. Many agents, including the MGMT inhibitor [19], PARP1 inhibitor [20], ribonucleotide reductase inhibitors [21], anti-epileptic drugs [22, 23], resveratrol

[24], rapamycin analogs [25] and cold atmospheric plasma [26] have been reported to enhance the sensitivity of TMZ [27]. However, further research remains until the usage of these agents at the clinical level.

The epigenetics is defined as a regulation of the gene expression by modifying the conformation of chromatin or DNA, that is not due to changes in the nucleotide sequence of the gene, but the changes persists for generation [28-30]. Epigenetic gene regulation is essential for the silencing of a multitude of cellular gene loci including embryonic development, maintenance of cell fates and X-chromosome inactivation [31-35], polycomb group (PcG) and trithorax group (trxG) proteins are considered as critical regulators [36]. TrxG gene expression remains in active state which is characterized by the methylation of histone H3 at Lys 4 (H3K4). On the other hand, PcG shows repressive function and counteracts this gene inactivation by tri-methylation of histone H3 at Lys27 (H3K27me3) [37]. PcG proteins were discovered first in the fruit fly *Drosophila melanogaster* development as repressors of Homeobox (*HOX*) genes, which are necessary for determining the body plan and the formation of body segments [38]. In mammalian cells, PcG proteins form large multimeric complexes that silence the target genes as well as *HOX* genes through chromatin modification such as acetylation and methylation [38, 39]. Recently, several studies have reported that the dysregulation of PcG proteins have been found in various cancer types including glioblastoma and strongly associate with a poor prognosis or metastasis [33, 40].

PcG proteins are classified into two distinct multi-protein complexes, the

polycomb repressive complex 1 (PRC1) and polycomb repressive complex 2 (PRC2) based on their roles for gene suppression [32]. PRC1 consists of BMI1/RING1/Mel-18 proteins which is required for the maintenance of silenced state through ubiquitination of histone H2A at lysine 119 (H2AK119ub), and participates in compaction of polynucleosomes [35, 41, 42]. These proteins play an important role in the regulation of differentiation and the maintenance of stem cell populations [31, 43]. PRC2 contains the PcG proteins such as enhancer of zeste homolog 2 (EZH2), supporting proteins suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED) [32] and is involved in the initiation of silencing through H3K27me3 [32, 44]. PRC2 catalyzes the H3K27me3 whereas PRC1 dynamically recruits the modified histones, which then mediates the ubiquitination of H2AK119 resulting in the repression of targeted genes. PRC2 leads to a more condensed chromatin and cooperates with histone deacetylases (HDAC), DNA methyltransferase (DNMT), co-repressor, etc [45, 46].

EZH2 contains the catalytic SET domain and transfers a methyl group from S-adenosylmethionine (SAM) when complexed with SUZ12 and EED [35, 47-51]. SUZ12 is required for the stabilization of EZH2 along with EED [31, 52, 53]. Several studies showed that EZH2 regulates the silencing of tumor suppressor genes (*e.g.*, p16^{INK4A}, ADRB2, DAB2IP, Kruppel-like foator) [54-58], the regulations of cell cycle (*e.g.*, EGFR2, p53, Wnt/b-catenin, Ras), invasion (*e.g.*, NF-kB, β -adrenergic signaling, E-cadherin), differentiation (*e.g.*, BMP, Notch signaling) and angiogenesis (*e.g.*, VEGF) [59-62]. In glioblastoma, EZH expression level increases

along with tumor grade and is also known to play a key role in stem cells maintenance [63, 64]. Down-regulation of EZH2 by RNA interference induces cell cycle arrest at G₀/G₁ phase and apoptosis in U87 human glioma cells [65]. However, many aspects of molecular mechanisms associated with EZH2 and glioblastoma cell proliferation are still unclear. Recent studies have shown that SUZ12 expression level is also elevated in several human cancers, signifying its importance in cell proliferation, invasion and blocking apoptosis [52, 66]. Although, SUZ12 plays a role in tumorigenesis, its molecular mechanisms in the progression of tumorigenesis are not yet clearly understood. Based on fact that the SUZ12 knockdown strongly impaired the EZH2 activity as well as expressions [52, 67, 68], I determined the substantial impact of PRC2 silencing in human glioblastoma. In order to investigate the tumorigenesis and chemoresistance by targeting PRC2 in glioblastoma, I generated PRC2-knockdown cell lines by using lenti-viral shSUZ12 system in T98G Cells.

From GBM genome analysis, the deletion of *CDKN2A/CDKN2B* locus and the amplifications of *EGFR*, *PDGFRA*, *CDK4* genes were reported to be involved in cell proliferation and the deficient frequency is as high as 46.4%, especially for *CDKN2A/CDKN2B* [69]. *CDKN2A/CDKN2B* loci is a target for PcG which is involved in cell senescence, regulation of the cell cycle, and maintenance of stemness [70-77]. If PcG delays the cell cycle process in glioblastoma, then there could be a possibility of another CDK inhibitor function other than *CDKN2A/CDKN2B*. The cyclin-dependent kinase inhibitor (CDKN1B) is a central

regulator of the cell cycle [78] leading to an arrest in the G₁-phase of the cell cycle by inhibiting the activity of Cyclin-CDK2 [79]. CDKN1B frequently acts as a potent tumor suppressor in many aggressive human cancers, and its inhibition is associated with poor prognosis in many cancers [80, 81]. Degradation of CDKN1B is regulated by two different mechanisms, one is by ubiquitin-mediated degradation and another is by proteolytic processing by 26S proteasome [82, 83]. In case of ubiquitin-mediated degradation, CDKN1B protein level is reduced due to the rapid protein degradation by ubiquitin protein ligase complex called SCF (SKP1-cullin-F-box) [84, 85]. The S-phase kinase protein, SKP2 is overexpressed in human cancers [86]. Down-regulation of SKP2 leads to G₁ arrest and growth inhibition [87]. SKP2 is a component of SCF complex, which is required for the ubiquitin-mediated degradation of several cell cycle regulators, such as the cell cycle inhibitor CDKN1B and Cyclin D1 [78, 88]. SKP2 recruits CDKN1B to the SCF complex and induces polyubiquitination and promotes for CDKN1B degradation through the 26S proteasome [78, 84, 89-91]. MYC, a proto-oncogenic transcription factor promotes cell proliferation and plays a central role in the genesis of many human cancers [92-95]. In human leukemia cells, SKP2 is known as a direct target to MYC and consequently leads to MYC-SKP2-CDKN1B axis [90, 96]. However, the existence of the MYC-SKP2-CDKN1B axis and its regulatory mechanisms in glioblastoma remains to be investigated.

Several lichen extracts have been used as the traditional folk medicine for the disease treatments and recent studies have suggested that lichen metabolites contain

many effective biological activities such as antibiotic, anti-mycobacterial, anti-viral, analgesic, and anti-pyretic [97, 98]. Antarctic lichen produce a great variety of secondary metabolites and most of them are unique because they have protective mechanisms to avoid DNA damage under extreme environment including high UV radiation and low temperature [99-101]. Therefore, the possibility of using lichen metabolites as potential and novel medical drugs has become a promising approach [97]. Recently several metabolites from the Antarctic lichen *Stereocaulon alpinum* have been isolated [97, 102, 103] and proved to have several biological activities such as antibacterial and antioxidant activity as well as protein tyrosine phosphatase 1B (PTP1B) inhibitory activity which acts as a negative regulator for insulin signaling [101]. Among several metabolites, lobarstin is known to play an important role as PTP1B inhibitor. However, its exact function is not yet clearly understood. Therefore, further studies are required to elucidate the molecular mechanism and its regulatory functions. My main aim of the present study is to develop effective anticancer drug for the difficult-to-treat glioblastoma patients. In order to achieve this goal, Firstly, I investigated on anti-proliferatory effects of PRC2 as a potential therapeutic target against human glioblastoma and found the molecular mechanism of PRC2 during cell cycle regulation in the PRC2-depleted T98G cells. PRC2-depletion increased the stability of CDKN1B protein via down-regulation of MYC in SKP2 pathway resulting in G₁ phase arrest during cell cycle. Secondly, I investigated PRC2 role in the regulation of chemosensitivity in glioblastoma cell line and proved that the PRC2 enhances TMZ-sensitivity via down-regulation of BER

genes such as *PARP1*, *XRCC1* and *LIG3*. Finally, I found that the co-treatment with lobarstin and TMZ enhances TMZ treatment efficiency through down-regulation of MGMT and PARP1 both transcriptionally and translationally.

Taken together, my present data showed that the PRC2 can be considered as a promising target for novel GBM therapeutic strategies and Lobarstin might be used as potential combinatorial drug for GBM therapy.

II. MATERIAL AND METHODS

1. Cell culture

Human glioblastoma T98G cells (generous gift from Dr. S. S. Kang of Gyeongsang National University, Korea) and the human embryonic kidney cell line 293T (generous gift from Dr. H. Y Chung of Hanyang University, Korea) were cultured in DMEM supplemented with 10% fetal bovine serum (J R Scientific, Woodland, CA, USA), 100 units/ml of penicillin and 100 µg/ml of streptomycin sulfate (Welgene, Daegu, Korea).

2. Reagents

TMZ, propidium iodide and cycloheximide were purchased from Sigma-Aldrich (St. Louis, MO, USA). RNase A was purchased from Bio Basic (Markham, Ontario, Canada) and Puromycin was purchased from InvivoGen (San Diego, CA, USA). TMZ was dissolved in DMSO. Cyclohexamide and BCNU were dissolved in Ethanol.

3. Plasmid preparation and transfections

3-1. Cloning short hairpin RNA into lenti-viral vector

For gene silencing, shLuc and shSUZ12 targeting CTTCGAAATGTCCGTTCCGGTT of firefly luciferase gene and AAGCTGTTACCAAGCTCCGTG of human SUZ12 gene respectively, were cloned into pLB lentiviral vector as described [104]. Packaging vectors were psPAX2 and pMD2.G purchased from Addgene (Cambridge, MA, USA).

3-2. Transfection of lenti-viral vector and transduction of lenti-virus

To generate infectious lenti-viral particles, HEK-293 T cells were cultured in D10 medium (DMEM containing 10% fetal bovine serum, 2 mM L-glutamine (Welgene), 10 mM HEPES (Welgene) and transfected at 70-80% confluence using the calcium phosphate precipitation method and 12 µg lentiviral shRNA construct, 8 µg psPAX2, and 6 µg pMD2.G. Following 12 hrs incubation, the culture medium was replaced with fresh virus production medium (D10 medium containing 1.28% BSA), supernatants containing viral-particles were collected 48 hrs later and centrifuged for 5 min at $3,000 \times g$ to remove cell debris. T98G cells were infected with lenti-viral supernatant with 8 µg/ml of protamine sulfate (Sigma) for 12 hrs and the medium was replaced with fresh medium. Gene knockdown was examined 48 hrs post-infection.

3-3. Cloning short hairpin RNA into retro-viral vector

For overexpression of MYC, coding sequence cloned into a retroviral expression vector, MFG-IRES-Puromycin (generous gift from Dr. H. Y. Chung of Hanyang University) and named Myc-MFG-IRES Puromycin. pMDG and HIV gag-pol encoding the proteins required for virus packaging were purchased from Addgene (Cambridge, MA, USA)

3-4. Transfection of retro-viral vector and transduction of retro-virus

To generate infectious retro-viral particles, HEK-293 T cells were cultured in D10 medium (DMEM containing 10% fetal bovine serum, 2 mM L-glutamine (Welgene), 10 mM HEPES (Welgene)) and transfected at 70-80% confluence using the calcium phosphate precipitation method and 16 µg retroviral shRNA construct, 6 µg HIV gag-pol and 2 µg pMD.G. Following 12 hrs incubation, the culture medium was replaced with fresh virus production medium (D10 medium containing 1.28% BSA). Virus-containing supernatant was collected 72 hrs later and centrifuged for 5 min at $3,000 \times g$ to remove cell debris. For infection, the culture medium was replaced by retro-viral supernatant supplemented with 8 µg/ml of polybrene (Sigma), and the cells were incubated at 37°C for 12 hrs. At 48 hrs after infection, virally transduced cells were selected by culture in 1 µg/ml of puromycin (InvivoGen, CA, USA) for 1 week and subjected to further analysis.

4. Cell viability assay

Water-soluble tetrazolium salt (WST) assay was performed with EZ-Cytox (DAEIL LAB SERVICE, DoGen; Seoul, Korea) as instructed by the manufacturer. Primary human fibroblasts and T98G cells were plated into 96 well plates (2×10^3 cells/well), respectively, and incubated overnight at 37°C. The cells were treated with drugs for indicated times, 10 μ l of WST solution (EZ-CyTox) was added to the cell, which were further incubated for 1hr. The absorbance at 450 nm was measured with a microplate reader (Bio-rad, Richmond, CA, USA).

5. Cell cycle analysis

The cells were collected by centrifugation at $3,000 \times g$ for 5 min, fixed in 70% ice-cold ethanol at 4°C for overnight and washed two times with $1 \times$ PBS containing 1% FBS, resuspended in 1 ml of $1 \times$ PBS containing 50 μ g/ml of RNase A and 50 μ g/ml of propidium iodide (Sigma-Aldrich), incubated in the dark for 10 min at room temperature and then analyzed using FACS canto II and FACSDiva software (BD bioscience, Franklin Lakes, NJ, USA)

6. Reverse transcription-polymerase chain reaction (RT-PCR)

6-1. RNA isolation

Total RNA was isolated according to the method of Chomczynski and Sacchi [105]. Briefly, cells were washed with cold PBS and lysed in solution D (4 M guanidium thiocyanate, 0.1 M β -mercaptoethanol, 0.5% sodium N-laurylsarcosine, 25 mM sodium citrate, pH 7.0), 0.1 volume of 2 M sodium acetate pH 4.0, 1 volume of water-saturated phenol, and 0.2 volume of chloroform:isoamyl alcohol (25:1) were added. After centrifugation, the aqueous phase was removed and RNA was precipitated with the addition of an equal volume of isopropanol. The RNA pellets were washed twice with 75% ethanol. Following centrifugation, RNA pellets were resuspended in RNase-free dH₂O. RNA quantity and quality were assessed by measuring the optical density at 260 and 280 nm.

6-2. cDNA synthesis and RT-PCR

cDNA was generated with M-MLV Reverse Transcriptase (Elpis Biotech, Daejeon Korea), followed by PCR with HiPi Plus ThermoStable DNA Polymerase (Elpis Biotech). Primers used for PCR are as follows.

SKP2-F	CGTGTACAGCACATGGACCT
SKP2-R	GGGCAAATTCAGAGAATCCA
MYC-F	ACC ACC AGC AGC GAC TCT GA
MYC-R	TCC AGC AGA AGG TGA TCC AGA CT
GAPDH-F	CTCAGACACCATGGGGAAGGTGA
GAPDH-R	ATGATCTTGAGGCTGTTGTCATA
MGMT-F	GCAATGAGAGGCAATCCTGT
MGMT-R	GTCGCTCAAACATCCATCCT
PARP1-F	GCT CCT GAA CAA TGC AGA CA
PARP1-R	CAT TGT GTG TGG TTG CAT GA
XRCC1-F	GAG GAT GAG GCC TCT CAC AG
XRCC1-R	TCC TCT GTG TCC CCA GAA TC
LIG3-F	GTG GAT TTG GGC ATG TAT CC
LIG3-R	GCC CAT TCC CCC TAT ACT GT
MPG-F	TGG CAC AGG ATG AAG CTG TA
MPG-R	GTG TCC TGC TCA GCC ACT CT
POLB-F	GAG AAG AAC GTG AGC CAA GC
POLB-R	CGT ATC ATC CTG CCG AAT CT
ACTIN-F	GGC ACC CAG CAC AAT GAA G
ACTIN-R	GCC GAT CCA CAC GGA GTA CT

7. Western blot analysis

Cells were lysed in RIPA buffer (10 mM Tris-HCl, 150 mM NaCl, 1 mM ethylenediamine tetraacetic acid, 1% sodium deoxycholate, 0.1% SDS and 1% Triton X-100, pH 7.4) with a protease-inhibitor cocktail (P2850, Sigma-Aldrich). Protein samples were separated by SDS–polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (GE Healthcare Life Sciences Whatman, Germany). After blocking (5 % non-fat dry milk), the membranes were probed with appropriate primary antibodies and peroxidase-conjugated secondary antibodies and protein bands were detected using a chemiluminescent substrate kit (Elpis Biotech). Immunoblots were visualized with ChemiDoc XRS system (Bio-Rad) and analyzed with ImageJ (NIH, Bethesda, MD, USA).

Western blot analysis was performed as described previously (17). Antibodies against MGMT, CDKN1B, Cyclin E, Cyclin D1, CDK2, CDK4, and SKP2 were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.), EZH2, MYC, PARP1, XRCC1 and GAPDH were from Cell Signaling Technology (Danvers, MA, U.S.A.), LIG3, MPG and Polβ were from GeneTex (Irvine, CA, U.S.A.), LAMIN B1 was from abcam and HRP-conjugated IgGs were from Jackson ImmunoResearch Laboratories (West Grove, PA, U.S.A.).

8. Immunostaining

Cells were seeded in 6 well plates (SPL Life Science, Pocheon, Korea) a density for 5×10^4 cells per well. The next day, cells were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde and permeabilized with 0.3% triton X-100 and 10% normal goat serum (NGS) in $1 \times$ PBS. Following cell fixation, cell were incubated with the appropriate primary antibodies in a solution of $1 \times$ PBS with 1% Bovine serum albumin and 0.3% Triton X-100 at 4°C for overnight. Staining was visualized using anti-rabbit Cy3, anti-mouse Alexa Fluor 594 and the labeled fluorescence was examined by fluorescence microscopy. Nuclei were counterstained using 4, 6-diamidino-d-phenylindole (DAPI; vectorlabs, Burlingame, CA, USA).

9. Alkaline comet assay

Alkaline comet assay was performed with the CometAssay Kit (Trevigen; Gaithersburg, MD, U.S.A.) as instructed by the manufacturer. After trypsinization, cells were washed with ice-cold PBS and suspended in a 0.5% (wt/vol) solution of low temperature-melting agarose in PBS (pH 7.4) at 37°C and immediately layered onto Comet Slides (Trevigen). The agarose was allowed to set for 30 min at 4°C and the slides were incubated in a lysis solution (25 mM NaCl, 100 mM EDTA, 10 mM Tris base, 1% sodium lauryl sarcosinate, and 0.01% Triton X-100; provided by Trevigen) at 4°C for 30 min in the dark. For the alkali comet assay, the slides were immersed in alkaline unwinding solution (200 mM NaOH, 1 mM EDTA) and then subjected to electrophoresis in alkali buffer at 1 V/cm at 4°C for 25 minutes. After rinsing twice in distilled water, the slides were dried at 45°C for 20min and then stained with SYBR Green. Images obtained by fluorescence microscopy (Olympus IX71 from Olympus; Tokyo, Japan) were subjected to analysis with Comet Assay IV v4.3 (Perceptive Instruments; Suffolk, United Kingdom). Statistical analysis of the results was performed as recommended by Bright *et al.*[106]. Briefly, 50 measurements of tail intensity (TI, also known as % tail DNA) obtained per treatment were normalized and expressed as fold-change relative to the vehicle-treated group. Results from three independent experiments were analyzed using a one-way ANOVA, followed by post hoc test using Scheffe (PASW Statistics for

Windows, Version 18.0 from SPSS Inc.; Chicago, IL, USA) to examine for group differences.

III. RESULTS

1. PRC2 regulates cell proliferation positively via modulation of the MYC-SKP2-CDKN1B axis in glioblastoma

1-1. PRC2 expression is up-regulated in T98G glioblastoma cells

PcG proteins such as PRC1 and PRC2 are highly associated with human cancers. The high expression of PRC2 is a hallmark of glioblastoma and implicated in tumorigenic potential and poor prognosis by inhibiting tumor suppressing related genes [64]. However, the role of PRC2 in glioblastoma is not clearly understood. In order to investigate the role of PRC2 in glioblastoma progression, I initialized the study by investigating the expression levels of PRC1 and PRC2 proteins in two human GBM cell lines (T98G and U87MG). Previously, it has been shown that U87MG and T98G cells express different expression levels of MGMT protein due to its methylation status and it is directly associated with the degree of sensitivity towards temozolomide [107]. For this purpose, I confirmed the expression level of PRC2 protein was high in MGMT-positive and TMZ-resistant T98G cells when compared to U87MG cell (Figure 1). Due to the facts that the expression level of PRC2 was high in T98G cell lines, I used this cell lines as an experiment models for further studies.




Figure 1. Expression of polycomb group genes in human Glioblastoma cell lines.

The expression levels of the PRC1 (BMI1, MEL18, RING1B), and PRC2 (EZH2, SUZ12) proteins in MGMT-positive T98G and MGMT-negative U87MG cells were analyzed by immunoblotting. The table in right panel represents the quantification of protein expression detected through immunoblotting. Results are representative of three independent experiments.

1-2. PRC2-depletion inhibits cell proliferation of GBM cells.

Previously, it was reported that the SUZ12-knockdown strongly impaired the EZH2 activity as well as its expression level [52, 67, 68]. Based on this report, I established shSUZ12-mediated PRC2 silencing system to investigate the role of PRC2 in glioblastoma progression. The result showed that the shSUZ12 effectively down-regulated the expression of SUZ12 as well as EZH2 in T98G cells (Figure 2A). I then investigated the effect of PRC2-depletion on the T98G cell proliferation, the depleted expression of PRC2 in T98G cells showed significant inhibition in glioblastoma cell proliferation (Figure 2B).



A**B**

Figure 2. PRC2-depletion inhibits the proliferation of T98G glioblastoma cells.

T98G cells were infected with shLuc (left lanes) or shSUZ12 virus (right lanes) for 48 hrs. Cells were harvested and subjected to immunoblotting to confirm the PRC2 depletion. (A) Expressions of PRC1 and PRC2 proteins were assessed with respective antibodies (individual proteins are indicated). GAPDH was used as an internal control. (B) T98G cells infected with shLuc (blackline) or shSUZ12 virus (gray line) for 48 hrs and seeded at 2,000 cells per well in 96-well flat-bottomed plates containing 0.1 ml medium was incubated up to 5 days. Cell proliferation was assessed every day up to 5 days by water-soluble tetrazolium salt (WST) assay. Data shown are representative of at least three independent experiments. Each bar represents the mean \pm S.D. from five separate experiments.

1-3. PRC2-depletion attenuates cell cycle progression at G₁ phase

To investigate the molecular mechanism of PRC2-mediated inhibition of cell proliferation, the cell-cycle analysis was performed using flow cytometry. The results showed that PRC2-depletion led to the cell accumulation in the G₁ phase. Eighty-four percent of PRC2-depleted T98G cells were at G₁ phase, as compared with 70% in control T98G cells (Figure 3A). These data indicated that the PRC2-depletion inhibits the T98G cell proliferation by inducing G₁ arrest. Next, the immunoblotting was performed to elucidate the protein expression levels of cell cycle regulators which are responsible for the G₁ arrest. As shown in Figure 3B, up regulation of Cyclin D1 and CDKN1B proteins were detected in the PRC2-depleted T98G cells. Taken together, these results support the notion that PRC2-depletion is sufficient to inhibit the proliferation of T98G glioblastoma cells.



A**B**


Figure 3. PRC2-depletion attenuates cell cycle progression at G₁ phase of glioblastoma cells

(A) Analysis of T98G cell cycle distribution by flow cytometry after shLuc and shSUZ12 infection. Cells were infected with shLuc or shSUZ12 virus for 48 hrs and stained with propidium iodide (PI) and the effect on cell cycle progression was monitored by FACS analysis. (B) Expression of the cell cycle regulators at G₁ phase was analyzed by immunoblotting. Results were obtained from the identical samples of (A). GAPDH was used as an internal control.

1-4. PRC2-depletion stabilizes and induces the nuclear accumulation of CDKN1B

I examined the protein levels of CDKN1B in cytoplasm and nucleus of PRC2-knockdown cells, because it is known that the CDKN1B acts as a CDK2 inhibitor, regulating cell cycle progression through the G₁ arrest. As shown in Figure 4A and 4B, PRC2-depletion caused a remarkable accumulation of CDKN1B in nucleus suggesting PRC2 depletion-mediated G₁ arrest was mainly associated with increased CDKN1B expression. To cross confirm this data, I performed immunofluorescence staining to estimate the expression level and distribution of CDKN1B in the PRC2-depleted T98G cells. The faint staining of CDKN1B observed in the control T98G cell; whereas a strong nuclear staining of CDKN1B observed in the PRC2-depleted T98G cells (Figure 4F). The CDKN1B expression patterns were inversely proportional to EZH2 expression. EZH2 is an epigenetic regulator and directly involved in transcriptional repression of several genes [108, 109]. In order to confirm whether CDKN1B is a direct target of EZH2 in the PRC2-depleted T98G cells, I measured the protein level of CDKN1B by Immunoblotting (Figure 4B) and the level of CDKN1B mRNA by RT-PCR (Figure 4C), and RT-q PCR (Figure 4D). The result showed that the levels of CDKN1B protein dramatically increased in the depleted expression of PRC2, though the CDKN1B mRNA expression level remained unchanged. To understand how CDKN1B was regulated post-transcriptionally in the PRC2-depleted T98G cell, I treated cells with protein

synthesis inhibitor cycloheximide (10 $\mu\text{g}/\text{mL}$; CHX) at different time intervals (0, 0.5, 1, 2, 4 hrs) and analyzed the CDKN1B expression level by Immunoblotting. As shown in Figure 4E, in the PRC2-depleted T98G cells, the degradation level of CDKN1B did not reduced by the cyclohexamide treatment when compared to the control cell. These results show that the depletion of PRC2 leads to the stabilization of CDKN1B protein through enhancing its half-life.









Figure 4. PRC2-depletion stabilizes and enhances nuclear accumulation of CDKN1B protein

(A) T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and expression of the EZH2 and CDKN1B were analyzed by immunoblotting, (C) RT-PCR (D) and RT-qPCR. (B) T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and then cells were harvested for isolation of cytosolic and nuclear proteins. Expression level of CDKN1B protein was analysed by immunoblotting. LAMIN B1 (nuclear protein) and HSP90 (cytosolic protein) expression were analyzed for successful fractionation. (E) Cycloheximide treated in a time dependent manner to analysis CDKN1B stability. Cells were harvested at 0, 0.5, 1, 2, 4 hrs after cycloheximide (10 µg/mL) addition and were analysed for CDKN1B protein levels by immunoblotting. ACTIN was used as an internal control. (F) T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and cells were fixed and immunostained with antibodies against EZH2, CDKN1B. Nuclei was stained with DAPI.

1-5. PRC2-depletion represses MYC-dependent SKP2 expression.

SKP2, the component of the SCF^{SKP2} E3 ubiquitin ligase, is required for the ubiquitination and degradation of phosphorylated CDKN1B protein which is expressed during the G₁ phase of the cell cycle [78, 90]. To determine whether PRC2-depletion has an effect on SKP2 expression level, I examined the expression of SKP2 protein and mRNA in the PRC2-depleted T98G cell lines. In reduced expression of PRC2, the SKP2 expressions were decreased both at the mRNA and protein levels (Figure 5). To identify the candidate genes for the SKP2 regulation, *MYC* gene was tested due to its direct association with SKP2 and also known to involve in MYC-dependent regulation of the SKP2 pathway which leads to CDKN1B degradation in leukemia cells [110]. To determine the effect of PRC2 in the regulation of MYC expression, I examined both at protein and mRNA levels of MYC in the PRC2-depleted T98G cells. This result showed that the MYC expressions were down-regulated both transcriptional and translational in the PRC2-depleted T98G cells (Figure. 6). Due to the fact that MYC is the upstream gene in the MYC-SKP2-CDKN1B axis [90] and depletion of PRC2 leads to MYC suppression, I hypothesized that the MYC could directly regulate SKP2 expression in T98G cells. To this end, I ectopically overexpressed MYC in T98G cell and investigated whether it alters any PRC2 depletion effect on SKP2 expression. Interestingly, in the MYC-overexpressed PRC2-depleted T98G cells, SKP2 inhibition completely rescued, in contrast, the levels of CDKN1B were markedly

inhibited (Figure 7). Taken together, these results suggest that PRC2 is involved in the regulation of MYC-SKP2-CDKN1B axis in glioblastoma cells.

A**B****C**

D




Figure 5. PRC2-depletion represses SKP2 expression

(A) T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and expressions of the SKP2 were analyzed by immunoblot, (B) RT-PCR (C) and RT-qPCR. GAPDH was used as an internal control. (D) T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and cells were fixed and immunostained with antibody against EZH2, SKP2. Nuclei were stained with DAPI.





Figure 6. PRC2-depletion down-regulates MYC-dependent SKP2 expression.

(A) T98G cells were infected with shLuc or shSUZ12virus for 48 hrs and expression of the MYC were analyzed by immunoblotting, (B) RT-PCR (C) and RT-qPCR. GAPDH was used as an internal control.

A



B




Figure 7. PRC2-depletion alters the expression of MYC-SKP2-CDKN1B axis in T98G cells.

First round of infection to T98G cells were carried out with MFG-IRES-puromycin (*Puro*) or MFG-*Myc*-IRES-puromycin (*Myc*) retroviruses. After 72 hrs of infection, selection was performed by puromycin (1 µg/ml) for 1 week, and then second round of infection was performed using shLuc or shSUZ12 virus for 48 hrs. Next, the cells were harvested to analyze (A) protein levels by immunoblotting. (B) The identical samples of (A) were analyzed by RT-PCR for indicated genes.

1-6. Comparison of the expression levels of EZH2, MYC, CDKN1B in human glioblastoma with normal specimens.

It is known that the high expressions of EZH2 [64, 111] and MYC [112] are related to disease progression in patients with glioblastoma [64, 111]. On the other hand, strongly reduced expression of CDKN1B correlates with progression of glioblastoma [113]. Therefore, the expression levels of EZH2, MYC and CDKN1B were estimated by immunoblotting from human glioblastoma patient's brain samples and normal brain samples. As previously reported, glioblastoma patients with up-regulated EZH2 expression showed enhanced MYC and reduced CDKN1B (Figure 8). Taken together, these results suggested that PRC2-depletion is responsible for the repression of glioblastoma cell proliferation via down-regulation of MYC-SKP2-CDKN1B axis (Figure 9).




Figure 8. Comparison of expression levels of selected proteins between human glioblastoma and normal brain samples.

Western blot analysis to determine the expression of EZH2, CDKN1B MYC from the glioblastoma patient's brain samples and normal brain samples. Actin was used as an internal control.





Figure 9. Hypothetical figure representation of PRC2 regulating MYC-SKP2-CDKN1B axis in human glioblastoma cells

2. PRC2-depletion increases chemosensitivity of drug-resistant human glioblastoma cells by repressing DNA repair system

2-1. PRC2-depletion enhances sensitivity for chemotherapeutic agents

Based on my previous observation that the knock down of PRC2 inhibits cell proliferation in glioblastoma, I hypothesized that the reduced PRC2 expression level might enhance chemosensitivity in glioblastoma when it is co-treated with chemotherapeutic agents. For this purpose, I established the PRC2-depleted cell lines using shSUZ12 to investigate the function of PRC2 in chemoresistance of glioblastoma. The generated PRC2-depleted cell lines were first validated for EZH2 and SUZ12 expression and found their expression levels were greatly reduced (Figure 10A). Then, I checked the effect of alkylating agent in both control cells and PRC2-depleted T98G cells. Results showed that the shLuc-infected T98G cells were relatively resistant to the alkylating agent, whereas PRC2-depleted T98G cells exhibit increased sensitivity for TMZ and BCNU treatment ($P < 0.05$; Figure 10B) suggesting PRC2 as a potential chemotherapeutic target for glioblastoma.

A. Western



B. Short term Cytotoxicity (MTS.)




Figure 10. PRC2 depletion in T98G cells dramatically increases the sensitivity for chemotherapeutic agents.

(A) T98G cells were infected with shLuc (left lanes) or shSUZ12 virus (right lanes) for 48 hrs. Cells were harvested and subjected to immunoblotting for confirm the PRC2 depletion. ACTIN was used as an internal control. (B) A cell viability assay was conducted to determine the effect of the PRC2-depletion and examine whether there was a synergetic effect with BCNU or TMZ in T98G cells.

2-2. The potentiation of TMZ by PRC2 depletion is associated with reduced DNA damage recovery

TMZ is known to induce the DNA damage through methylation of O⁶, N⁷-position of guanine, and the N³-adenine residues [12, 114]. I concerned with determining the influence of PRC2 during TMZ-induced DNA damage and repair. For this purpose, I studied the extent of DNA damage and repair by alkaline comet assay in shLuc and shSUZ12 infected T98G cells (Figure 11). The principle underlying the comet assay is that undamaged DNA remains tightly coiled and migrates slower under an electrophoretic field and resides in nucleoid, whereas damaged DNA (denatured and cleaved DNA fragments) migrate out of the nucleoid producing the comet tail. The tail intensity allows for assessment of the amount of DNA damage [106]. PRC2-depletion alone had minimal effect on DNA damage, as the tail intensity was similar to that of control T98G cells (Figure 11, Vehicle). I next examined the effect of PRC2 depletion on DNA damage and repair by treating T98G cells with 500 μ M TMZ for 2 hrs (TD). After 2 hrs of TMZ treatment cells were washed and incubated with fresh culture medium for 8 h T (R_8h), 24 h T (R_8h), to measure recovery from DNA damage. Results showed that the DNA repair rate was significantly decreased in the PRC2-depleted cells treated with TMZ compared to the controls (Figure 11). Taken together, these results suggest that the potentiation of TMZ efficiency was achieved by the knockdown of PRC2 leading to reduction in DNA repair activity in the PRC2-depleted T98G cells.



A**B**

Figure 11. Potentiation of TMZ by PRC2-depletion is associated with reduced DNA damage recovery.

shLuc and shSUZ12 virus infected T98G cells were treated with 500 μ M TMZ. After 2 hrs, media were replaced with fresh media for indicated time points and followed by alkaline comet assay. (A) Fluorescent image of cells subjected to alkaline comet assay. [V, vehicle; T (D), TMZ (damage); T (R), TMZ (recovery)] (B) Graphical representation of alkaline comet assay results. Results are shown as average of fold-change relative to control T98G from 50 measurements obtained per treatment and three independent experiments (total of 150 measurements) and standard deviation as error bars.

2-3. PRC2-depletion down-regulates the expression level of DNA repair related genes


In my previous results, PRC2-depletion enhanced the cytotoxicity of TMZ and decreased the repair activity in glioblastoma. It is well-known that the role of MGMT and BER in repairing the TMZ-induced DNA lesions [11, 115]. In order to investigate the effects of PRC2-depletion on DNA damage and repair, MGMT expression level was validated in the PRC2-depleted T98G cells along with control cell. Interestingly, there was no significant difference in MGMT protein level in both PRC2-depleted T98G cells and control cells (Figure 12A).

Next, I estimated the expression levels of several BER genes known to be involved in DNA repair and caused by TMZ-induced DNA damages (N3, N7-methyl adduct). Among these genes, the expressions of PARP1, XRCC1, and Lig3 were significantly down-regulated in the PRC2-depleted T98G cells both protein (Figure 12B) and mRNA level (Figure 12C), however other BER protein levels remain unaltered. These data indicated PRC2-depletion regulated the base excision repair during TMZ-induced DNA damage. In addition, it is well known that the PARP1 is a component of the base excision repair and plays an important role in the repair of TMZ-induced DNA damage in nucleus. I also showed that the nuclear PARP1 expression was significantly reduced in the PRC2-depleted cells during TMZ-induced DNA damage (Figure 13).

A. Western



B. Western



C. RT-PCR




Figure 12. PRC2 depletion in T98G cells inhibits the expression of DNA repair associated genes.

(A) T98G cells were infected with shLuc (left lanes) or shSUZ12 virus (right lanes) for 48 hrs. The expressions of MGMT and EZH2 were confirmed by immunoblotting (B) Expressions of the base excision repair genes were analyzed by immunoblotting and (C) by RT-PCR. ACTIN was used as an internal control.





Figure 13. PRC2-depletion inhibits PARP1 expression in nucleus.

T98G cells were infected with shLuc or shSUZ12 virus for 48 hrs and treated with 500 μ M TMZ for 24 hrs. Followed by cytosol/nuclear extraction, the expression level of PARP1 was analysed by immunoblotting. Lamin B1 (nuclear protein) and GAPDH (cytosolic protein) expression confirmed successful fractionation.


2-4. Comparison of expression levels of EZH2, MGMT and PARP1 in human glioblastoma samples with normal brain samples.

The expression of EZH2 is highly related to disease progression in patients with glioblastoma [64, 111] and PARP1 protein is detectable in GBM cells, but is undetectable in normal brain tissue [116]. MGMT expression level showed association with TMZ resistance in the GBM cell line. Thus, I measured EZH2, MGMT and PARP1 expression levels in human glioblastoma and normal brain tissue by immunoblotting. Results showed that the EZH2 expression level was up-regulated in glioblastoma tissue, and also enhanced PARP1 and MGMT expression (Figure 14). Taken together, these result suggested the notion that PRC2-depletion enhances TMZ efficiency via down-regulation of BER genes such as PARP1, XRCC1, LIG3 (Figure 15).

EZH2



MGMT



PARP1




Figure 14. Comparison of expression levels of EZH2, MGMT and PARP1 between human glioblastoma samples and normal brain samples.

I estimated the expressions levels of EZH2, MGMT and PARP1 from glioblastoma multiforme patients samples and compared with that of normal brain tissues samples by immunoblotting. Analysis of protein expression was normalized within each sample to the expression of ACTIN as controls.





Figure 15. Hypothetical figure representation of PRC2 regulating base excision repair in human glioblastoma cells

3. Lobarstin enhances chemosensitivity in human glioblastoma T98G cells

3-1. Lobarstin inhibits the cell viability of glioblastoma cell

Treatment of lobarstin (Figure 16A) was performed at increasing doses for three days on T98G glioblastoma cells. As seen in Figure 16B, lobarstin showed cytotoxic effect on T98G at a concentration as low as 10 μM ($n=5$, $p=0.002$, Student's t-test). Whereas the cytotoxic effect of lobarstin was not observed on human normal fibroblast even at 40 μM (Figure 16B; $n=3$, $p=0.108$, Student's t-test). Since, the dose at 40 μM was relatively toxic to T98G cells ($n=5$, $p=5.16\text{E-}05$, Student's t-test) while it was a tolerated dose for normal fibroblasts, I used 40 μM as the treatment dose concentration for my further experiments.

A



B




Figure 16. Chemical structure and cytotoxicity of lobarstin. (A) Chemical structure of lobarstin. (B) Primary human fibroblasts (Normal) and T98G (Glioblastoma) cells were tested for cell viability with lobarstin as described in Materials and methods. Cells were treated with indicated doses of lobarstin for 72 hrs. Results were shown as average of three (Normal) and five (T98G) independent experiments with standard deviation as error bars.

3-2. Co-treatment of lobarstin with TMZ enhances cytotoxicity

In general, TMZ is used as a standard chemotherapeutic agent for glioblastoma, but it is less effective to the patients expressing MGMT, a gene responsible for repairing alkylation induced by TMZ at the O⁶-position of guanine, than those who do not [117]. Initially, I checked the expression level of MGMT in T98G and U87MG cell lines and found that the expression level was significantly high in T98G cell lines (Figure 17A). Therefore, I wished to pursue my research on T98G cells expressing high MGMT, rendering more resistant to TMZ to investigate therapeutic effect of lobarstin [118]. TMZ treatment on T98G cells at increasing concentration showed statistically significant toxicity in all the conditions tested (Student's t-test, not shown), particularly the toxicity was more prominent at high doses of 500 and 750 μ M (Figure 17B). Co-treatment of lobarstin with high doses of TMZ on T98G cells resulted in enhanced toxicity when compared with only TMZ treatment (Figure 17C). These results suggest that lobarstin might provide additional toxicity effect along with TMZ or enhances toxicity effect of TMZ on cells.




A**B****C**

Figure 17. Lobarstin potentiates the sensitivity of TMZ in MGMT-positive T98G cells.

(A) Expression of MGMT in T98G cells. Expression at mRNA (left panels, RT-PCR) and protein (right panels, Immunoblot) levels were shown. MGMT-negative U87MG cells were used as negative control for MGMT expression. GAPDH was used as an internal control. (B) Cytotoxicity of TMZ on T98G cells. T98G cells were treated with indicated doses of TMZ for 72 hrs (3 d) or 96 hrs (4 d). (C) The effect of concomitant treatment of lobarstin and TMZ on T98G cell viability. Cells were treated with indicated combination of drugs for 72 hrs. T, 500 μ M TMZ; V, vehicle; L, 40 μ M lobarstin. Student's *t*-test, * P <0.05, 9dla** P <0.01. Results were shown as representative (A) or average of three independent experiments with standard deviation as error bars (B and C).

3-3. Reduced recovery from TMZ-induced DNA damage by lobarstin.

TMZ is known to damage DNA by methylating guanine (at O⁶ and N⁷ positions) and/or adenine (at N³ position) residues [114]. Firstly, I wished to check the effect of lobarstin on DNA damage. Therefore, I quantified DNA damage exhibited by the treatment of only TMZ or along with lobarstin by the alkaline comet assay (Figure 18). My result showed that the lobarstin-alone at 40 μ M for 26 hrs had minimal effect on DNA damage, as the tail intensity (TI) was similar to that of vehicle-treated cells for 26 hrs (Figure 18, L vs. V). Then, I examined the effect of co-treatment of lobarstin with TMZ on DNA damage, by treating T98G cells with 500 μ M TMZ-alone or with lobarstin for 2 hrs. Treatment duration was fixed to 2 hrs because in this 2hrs treatment, both TMZ and TMZ/lobarstin treated conditions showed similar-extent of DNA lesion [Figure 18, T(D) vs. LT(D)] and the time was long enough to induce DNA damage but short enough not to overlap with the DNA repair system induced upon DNA damage [Figure 18A;Damage(D)]. Therefore, cells were washed after 2 hrs of drug treatment and incubated with fresh culture medium to measure recovery from DNA damage [Figure 18A; Recovery(R)]. When damaged cells were challenged with fresh medium for 24 hrs, the cells incubated with lobarstin-containing medium showed higher TI than those with vehicle treated cells [Figure 18, T(R) vs. LT(R)]. Using one-way ANOVA to examine the group differences, statistical significance was seen between the groups [F(1,5) = 4058.828, p<0.001]. Results obtained by utilizing the post-hoc test using Scheffe were as follows: (1) Significant difference observed between V and T(D), and between T(D) and T(R),

p<0.001; (2) significant difference between L and LT(D), and between LT(D) and LT(R), p<0.001; (3) no significant difference between V and L, p=1.000; (4) no significant difference between T(D) and LT(D), p=0.998; and (5) significant difference was observed between T(R) and LT(R), p<0.001. Taken together, these results suggest that lobarstin-alone may not induce DNA damage, but the DNA damage induced by TMZ may be sustained in the presence of lobarstin.





A**B****C**

Figure 18. Effect of lobarstin on DNA damage and recovery. (A) Experimental paradigm of lobarstin and/or TMZ treatment for alkaline comet assay. Damage (D) and recovery (R) were defined in the solid line shown on the top (not drawn to scale). Six different experimental conditions were shown underneath the solid line as arrow [V, vehicle; L, lobarstin; T (D), TMZ (damage); LT (D), lobarstin and TMZ (damage); T (R), TMZ (recovery); and LT (R), lobarstin and TMZ (recovery)]. Alkaline comet assay was performed at the end of each arrow. (B) Fluorescent image of cells subjected to alkaline comet assay. (C) Summary of alkaline comet assay. Results are shown as average of fold-change relative to the vehicle-treated group from 50 measurements obtained per treatment and three independent experiments (total of 150 measurements) and standard deviation as error bars.

3-4. Down-regulation of DNA repair related genes by lobarstin.

As I observed that the lobarstin-treated cells showing reduced recovery from DNA damage in the alkaline comet assays, I hypothesized that the effect of lobarstin might affect the expression level of DNA repair related genes. To this end, I checked whether the treatment of T98G cells with lobarstin-alone for up to 48 hrs and found that the expression of MGMT and PARP1 which are implicated in DNA repair was dramatically decreased, in a time-dependent manner (Figure 19A, left panels). In addition, reduced mRNA expression was also observed for MGMT and PARP1 indicating negative regulation of lobarstin on these genes at its transcription level (Figure 19A, right panels). Moreover, co-treatment of lobarstin with TMZ resulted in significant reduction in MGMT, PARP1, LIG3 and XRCC1 protein levels (Figure 19B). Taken together, these results show that the increased chemotherapeutic sensitivity of glioblastoma by lobarstin might be due to the down regulation of DNA repair related genes (Figure 20).

A



B




Figure 19. Effect of lobarstin on the expression of DNA repair genes.

(A) The effect of lobarstin on DNA repair genes. Cells were treated with 40 μ M lobarstin for indicated times (left panels) or for 24 hrs (right panels) and subjected to immunoblot and RT-PCR, respectively. (B) The effect of 40 μ M lobarstin and/or 500 μ M TMZ on DNA repair genes. Cells were treated with indicated drugs for 24 hrs and subjected to immunoblot. Shown are representative results of three independent experiments. V, vehicle; L, lobarstin only; T, TMZ only; LT, lobarstin and TMZ.




Figure 20. Hypothetical figure representation of lobarstin regulating repair system in human glioblastoma cells

IV. DISSCUSSION

Epigenetic gene regulation by polycombgroup proteins is essential for embryonic development and its maintenance [31, 32]. PcG proteins were found to be overexpressed in various cancers through down-regulation of tumor suppressor genes involved in the carcinogenesis and poor prognosis. PcG is reported to be involved in self-renewal of cancer stem cells as well as normal cell [119-125], its mechanism involve in the negative regulation of locus CDKN2A/CDKN2B (INK4A/ARF) [73-77, 126]. Recently, several reports have been suggested that the microRNA (miRNA) regulates PcG roles such as cancer cell proliferation, migration, maintenance of stemness, angiogenesis, etc [127-131]. In addition, PcG also shows a characteristic of anti-cancer drug resistance in several cancer cells [47-49]. Based on the previous reports, there could be high possibility of controlling cancer cell growth by regulating the PcG expression levels. Thus, further research on alteration of PcG expressions and its effect on cancer cells are much needed.

EZH2, SUZ12 and EED are the components of PRC2, is one of the two classes of PcG proteins [32] which are mainly involved in transcriptional repression [32, 44]. Among these proteins, EZH2 acts mainly as a gene silencer which is involved in chromatin condensation by transferring a methyl group to H3K27 [47-49, 132]. SUZ12 is mainly required to stabilize EZH2 protein. It has been reported that the knock-down of SUZ12 by small interfering RNA led to down-regulation of EZH2

expression, and subsequently leading to the inhibition of EZH2-mediated histone methyltransferase activity [48, 68, 133]. In order to investigate whether PRC2 could serve as a therapeutic target against GBM, I generated PRC2-depletion system using shSUZ12 lentivirus because shSUZ12 was more effective than the shEZH2 on PRC2-mediated gene regulation in my experiments.

CDKN1B has a critical role in G₀ and early G₁ phase of the cell cycle inhibiting the activity of Cyclin/Cdk complexes [80]. In glioblastoma, reduced expression of CDKN1B is associated with poor prognosis and increased cell proliferation [113, 134]. *SKP2* has oncogenic properties and plays a critical role in cell cycle progression through degradation of cell cycle regulator such as CDKN1B, Cyclin D1 [135]. Firstly, I investigated the anti-proliferation activity of PRC2 on T98G glioblastoma cells by depleting the PRC2 expression level using shSUZ12 lentivirus and observed that the cell growth was dramatically decreased in T98G cells. It is well known that PRC2-depletion down-regulates *MYC* expression and further *SKP2* is a direct target to *MYC* [90]. In line with previous reports, my results showed that the PRC2-depletion induces G₁ phase cell arrest via regulation of *MYC-SKP2-CDKN1B* axis resulting in the stabilization and enhancement of CDKN1B protein. Recently, it has been reported that the up-regulation of EZH2 expression was regulated by *MYC* [136], however, there was no evidence whether the EZH2 leads to the down-regulation of *MYC* expression. In my result, PRC2 act as a negative regulator or the gene regulating *MYC* expression levels even though PRC2 is not a direct target to *MYC*. Therefore, identification of the negative regulator that

regulates *MYC* under PRC2 depletion would be necessary.

Recent studies have shown that the malignant transformation is correlated with the overexpression of *MYC*, *SKP2* and down-regulation of *CDKN1B*. In this study, *EZH2* depletion leads to high *CDKN1B* protein level via repression of *MYC*-dependent *SKP2* pathway. My study also proves the anti-proliferation activity of PRC2 as a potential therapeutic target against human glioblastomas. However, further research has to be carried out to investigate the candidates involved in regulating *MYC* in the PRC2-depleted cells.

Treatment of GBM often fails because these tumors are highly resistant to the current anticancer therapy such as chemotherapy and radiation therapy [137, 138]. Currently, TMZ is most widely used as a standard chemotherapeutics for glioblastoma [8]. However, TMZ-induced DNA damage resistant was also reported in a number of cases due to active DNA repair systems [139]. Therefore, various approaches are in progress in order to modulate or control proteins expression levels that are related to DNA repair system to overcome the TMZ resistance, among them are MGMT inhibitor [140], poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [116, 141], N-methylpurine DNA glycosylase (MPG), DNA polymerase β (Pol β) [10, 142] and AP endonuclease (APE-1) inhibitors [143]. The DNA repair mechanisms in TMZ-induced DNA damage mainly includes BER, MGMT and MMR and also it is evident that T98G cells show strong expression of these repair pathways. Among these repair systems, I focused mainly on BER because of the high MGMT expression levels in the PRC2-depleted T98G cells. A key component of base excise

repair is *PARP1* which is activated in response to DNA damage and binds to the single-stranded DNA breaks and function as a DNA damage sensor [11, 144, 145]. *PARP1* catalyze the poly (ADP-ribosylation) from NAD⁺ to itself and to nuclear acceptor proteins, generating long chains of poly ADP-ribosylated polymers [146] and subsequently recruits the DNA repair proteins such as scaffolding protein *XRCC1*, *Polβ*, *LIG3* to the damaged sites and then accomplish the repair mechanism [142, 147-149]. In an attempt to develop effective anticancer drugs for glioblastoma therapy, the role of *PRC2* and the effects of lobarstin was examined in T98G glioblastoma cells. In this study, I reported that *PRC2*-depleted T98G cells were more sensitive to TMZ than in T98G control cells. Additionally, I observed the down-regulation of several BER proteins such as *PARP1*, *XRCC1*, and *LIG3* in the *PRC2*-depleted T98G cells suggesting the suppression of base excision repair mechanism.

It has been reported that the increase in chemosensitivity of cancer cells by alkylating agents was through regulation of the BER pathway suggesting the possibility of modulating BER pathway as a potential target for chemotherapeutics. In line with the previous studies, my study suggested that the *PRC2*-depleted T98G cells showed increased chemosensitivity to TMZ via down-regulation of BER despite exhibiting the high *MGMT* expression levels. In conclusion, I suggest that the *PRC2* is a target protein responsible for enhancing the TMZ cytotoxicity of GBM cells. However, further studies are essential to determine the direct targets for *PRC2* which are responsible for regulating the inhibition of *PARP1*, *XRCC1*, *Lig3*.

Thus, there could be a possibility of developing PRC2 as a potential target for overcoming the problem of drug resistance in GBM patient.

Finally, I reported molecular functions of lobarstin in enhancing the TMZ-sensitivity in chemoresistant glioblastoma T98G cells. I observed reduced recovery of DNA damage in cells co-treated with lobarstin and TMZ, indicating that the lobarstin is mainly involved in the down-regulation of DNA repair related gene expressions. Suppression of MGMT expression followed by TMZ treatment has been reported previously [150]. In contrast, induction of MGMT expression by TMZ treatment has been reported as well [151]. Such discrepancies may be attributed due to differences in the TMZ treatment conditions, as prolonged exposure to low-dosage of TMZ is predicted to acquire chemoresistance [152]. Although I used a high dose of TMZ at 500 μ M in my present study, long-term effect of lobarstin treatment on the MGMT expression levels and its regulation on DNA repair related genes are yet to be investigated. Furthermore, it would be intriguing to investigate the effect of lobarstin with other clinically-utilized therapies, such as radiotherapy [153], carmustine [154] and bevacizumab [155]. Despite standard therapy, GBM is known to present an extremely high incidence of recurrence (~90%) [156]. It has been suggested that a sub-population of therapy-resistant cells with stem cell-like characteristics are responsible for tumor re-growth [157]. Although these cells may be highly heterogeneous, thus extremely difficult to characterize, eradication of these tumor-initiating cells would be pivotal in the complete cure of this fatal disease [157, 158]. It would be very interesting to examine the effect of lobarstin in a

population of cells called side-population, which behaves like stem cells and is resistant to chemotherapeutic treatments [159]. Because multiple gene expression was up or down regulated by lobarstin, I can predict that lobarstin may modulate the expression and/or activity of critical transcription factor(s). GATA4 may be an interesting candidate to examine its correlation with lobarstin for future research, because the expression of the BER enzyme alkylpurine DNA N-glycosylase was reduced by GATA4 [160]. Although, lobarstin reported as a metabolite isolated from *Stereocaulon alpinum*, which act as a potent inhibitor of protein tyrosine phosphatase N1 (PTPN1) [97], the exact biological activity of lobarstin remains to be elucidated. Further, testing for the possibility of lobarstin as a phosphatase inhibitor would be intriguing, as PTPN1 is actively pursued as a drug target for various diseases, including cancer [161, 162]. In conclusion, I showed the functions of lobarstin in enhancing the sensitivity of GBM cells to TMZ. I also suggested a possible molecular mechanism of lobartin in down regulating DNA repair related gene expressions. These results open the possibility of lobarstin as a potential factor for GBM combination therapy.

As compared with normal brain samples, EZH2 expressed predominantly high in glioblastoma patient samples suggesting the epigenetic PRC2 activity may participate in the progression of tumorigenesis and cell growth rate of GBM. My study results showed that shSUZ12-mediated PRC2-depletion leads to glioblastoma growth inhibition and increased TMZ potentiation. However, how PRC2 regulate the *MYC* and BER proteins remains to be examined because the PRC2 is a

methyltransferase and play a critical role as transcriptional repressor. Therefore, further research including identification of target genes that are positively regulated by PRC2 complex would be essential. Taken together, my research results provide an informative theoretical foundation to develop PRC2 depletion as a potential strategy for GBM therapy and lobarstin as a combination drug for GBM treatment.

V. REFERENCES

1. Holland EC: Glioblastoma multiforme: the terminator. *Proceedings of the National Academy of Sciences of the United States of America* 2000, 97(12):6242-6244.
2. Gagliano N, Costa F, Cossetti C, Pettinari L, Bassi R, Chiriva-Internati M, Cobos E, Gioia M, Pluchino S: Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. *Oncology reports* 2009, 22(6):1349-1356.
3. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. *Cancer-Am Cancer Soc* 1988, 62(10):2152-2165.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U *et al*: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *The New England journal of medicine* 2005, 352(10):987-996.
5. Buckner JC: Factors influencing survival in high-grade gliomas. *Seminars in oncology* 2003, 30(6 Suppl 19):10-14.
6. Wen PY, Kesari S: Malignant gliomas in adults. *The New England journal of medicine* 2008, 359(5):492-507.
7. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN: Molecularly targeted therapy for malignant glioma. *Cancer-Am*

- Cancer Soc* 2007, 110(1):13-24.
8. Yamauchi T, Ogawa M, Ueda T: Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. *Molecular pharmacology* 2008, 74(1):82-91.
 9. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW: Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD(+) Biosynthesis and Base Excision Repair. *Cancer Res* 2011, 71(6):2308-2317.
 10. Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW: N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. *Neuro-oncology* 2011, 13(5):471-486.
 11. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008, 14(10):2900-2908.
 12. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat Rev* 1997, 23(1):35-61.
 13. Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B, Graziani G: N3-methyladenine induces early poly(ADP-

- ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity. *Molecular pharmacology* 2005, 67(2):572-581.
14. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL *et al*: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. *J Clin Invest* 2012, 122(1):253-266.
 15. Kinsella TJ: Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers. *Clinical Cancer Research* 2009, 15(6):1853-1859.
 16. Demurcia G, Demurcia JM: Poly(Adp-Ribose) Polymerase - a Molecular Nick-Sensor. *Trends Biochem Sci* 1994, 19(4):172-176.
 17. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. *Pharmacol Rev* 2002, 54(3):375-429.
 18. Liu LL, Gerson SL: Targeted modulation of MGMT: Clinical implications. *Clinical Cancer Research* 2006, 12(2):328-331.
 19. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE: Effect of O6-Benzylguanine Analogs on Sensitivity of Human Tumor-Cells to the Cytotoxic Effects of Alkylating-Agents. *Cancer research* 1991, 51(13):3367-3372.
 20. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G: Poly

- (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. *Glia* 2002, 40(1):44-54.
21. Figul M, Soling A, Dong HJ, Chou TC, Rainov NG: Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. *Cancer chemotherapy and pharmacology* 2003, 52(1):41-46.
 22. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD: Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. *Neuro-oncology* 2010, 12(9):917-927.
 23. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P *et al*: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology* 2011, 77(12):1156-1164.
 24. Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. *Free Radical Bio Med* 2012, 52(2):377-391.
 25. Grzmil M, Hemmings BA: Overcoming resistance to rapalogs in gliomas by combinatory therapies. *Bba-Proteins Proteom* 2013, 1834(7):1371-1380.
 26. Koritzer J, Boxhammer V, Schafer A, Shimizu T, Klampfl TG, Li YF, Welz

- C, Schwenk-Zieger S, Morfill GE, Zimmermann JL *et al*: Restoration of Sensitivity in Chemo - Resistant Glioma Cells by Cold Atmospheric Plasma. *Plos One* 2013, 8(5).
27. Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J: The strategy for enhancing temozolomide against malignant glioma. *Frontiers in oncology* 2012, 2:98.
 28. Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. *Molecular cancer therapeutics* 2009, 8(6):1409-1420.
 29. Margueron R, Reinberg D: The Polycomb complex PRC2 and its mark in life. *Nature* 2011, 469(7330):343-349.
 30. Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. *Cell* 2012, 150(1):12-27.
 31. Gieni RS, Hendzel MJ: Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. *Biochemistry and cell biology = Biochimie et biologie cellulaire* 2009, 87(5):711-746.
 32. Campbell S, Ismail IH, Young LC, Poirier GG, Hendzel MJ: Polycomb repressive complex 2 contributes to DNA double-strand break repair. *Cell Cycle* 2013, 12(16):2675-2683.
 33. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL *et al*: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human

- nasopharyngeal epithelial cells. *The Journal of clinical investigation* 2009, 119(12):3626-3636.
34. Simon JA, Kingston RE: Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. *Molecular cell* 2013, 49(5):808-824.
 35. Watson Z, Dhummakupt A, Messer H, Phelan D, Bloom D: Role of polycomb proteins in regulating HSV-1 latency. *Viruses* 2013, 5(7):1740-1757.
 36. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins. *Cell* 2007, 128(4):735-745.
 37. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, Orkin SH: Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. *Nat Chem Biol* 2013, 9(10):643-650.
 38. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer; the polycomb connection. *Cell* 2004, 118(4):409-418.
 39. Chato W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F, Bernier G: The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2009, 29(2):529-542.
 40. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O,

- Haukaas SA, Salvesen HB, Otte AP, Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006, 24(2):268-273.
41. Francis NJ, Kingston RE, Woodcock CL: Chromatin compaction by a polycomb group protein complex. *Science* 2004, 306(5701):1574-1577.
 42. Cao R, Tsukada Y, Zhang Y: Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. *Molecular cell* 2005, 20(6):845-854.
 43. Ismail IH, McDonald D, Strickfaden H, Xu Z, Hendzel MJ: A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. *The Journal of biological chemistry* 2013, 288(37):26944-26954.
 44. Cao R, Wang LJ, Wang HB, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y: Role of histone H3 lysine 27 methylation in polycomb-group silencing. *Science* 2002, 298(5595):1039-1043.
 45. Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M: Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. *Molecular and cellular biology* 2005, 25(24):11047-11058.
 46. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D: Histone methyltransferase activity associated with a human multiprotein

- complex containing the Enhancer of Zeste protein. *Genes & development* 2002, 16(22):2893-2905.
47. Pasini D, Bracken AP, Jensen MR, Denchi EL, Helin K: Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. *Embo J* 2004, 23(20):4061-4071.
48. He AB, Shen XH, Ma Q, Cao JJ, von Gise A, Zhou PZ, Wang G, Marquez VE, Orkin SH, Pu WT: PRC2 directly methylates GATA4 and represses its transcriptional activity. *Gene Dev* 2012, 26(1):37-42.
49. Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR: The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. *Oncogene* 2013, 32(7):930-938.
50. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. *Cell* 2007, 128(4):669-681.
51. Bracken AP, Helin K: Polycomb group proteins: navigators of lineage pathways led astray in cancer. *Nat Rev Cancer* 2009, 9(11):773-784.
52. Cui Y, Chen J, He Z, Xiao Y: SUZ12 depletion suppresses the proliferation of gastric cancer cells. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology* 2013, 31(6):778-784.
53. Cao R, Zhang Y: SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. *Molecular*

- cell* 2004, 15(1):57-67.
54. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H: Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. *Nat Cell Biol* 2010, 12(11):1108-1114.
 55. Chen H, Tu SW, Hsieh JT: Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. *J Biol Chem* 2005, 280(23):22437-22444.
 56. Yu J, Cao Q, Mehra R, Laxman B, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS *et al*: Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. *Cancer cell* 2007, 12(5):419-431.
 57. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y: pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. *Genes & development* 2007, 21(1):49-54.
 58. Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, Haberler C, Aronica E, Vandertop WP, Noske DP *et al*: EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. *Clin Cancer Res* 2012, 18(15):4048-4058.
 59. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A: Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. *Leukemia* 2007, 21(5):1116-1122.

60. Kirmizis A, Bartley SM, Farnham PJ: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. *Molecular cancer therapeutics* 2003, 2(1):113-121.
61. Kleer CG, Cao Q, Varambally S, Shen RL, Ota L, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF *et al*: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *P Natl Acad Sci USA* 2003, 100(20):11606-11611.
62. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. *Blood* 2001, 97(12):3896-3901.
63. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L *et al*: EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. *Cancer research* 2009, 69(24):9211-9218.
64. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G: Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. *Neuropathology and applied neurobiology* 2011, 37(4):381-394.
65. Zhang RJ, Wang RJ, Chang H, Wu F, Liu CT, Deng DF, Fan WH: Downregulation of Ezh2 expression by RNA interference induces cell cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma cells. *Oncol*

- Rep* 2012, 28(6):2278-2284.
66. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li TY, Hua X, Landen CN, Birrer MJ, Sanchez-Beato M *et al*: SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK. *Mol Cancer Res* 2012, 10(11):1462-1472.
67. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E, Nomdedeu JF, Jenuwein T, Pelicci PG, Minucci S *et al*: Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. *Cancer cell* 2007, 11(6):513-525.
68. Turgeon N, Blais M, Delabre JF, Asselin C: The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response. *Journal of cellular biochemistry* 2013, 114(5):1203-1215.
69. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. *J Neuro-Oncol* 2010, 96(2):169-179.
70. Bruggeman SWM, Valk-Lingbeek ME, van der Stoop PPM, Jacobs JJJ, Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S *et al*: Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes & development* 2005, 19(12):1438-1443.
71. Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J,

- Helin K, Hansen KH: Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. *Embo J* 2007, 26(6):1637-1648.
72. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP: SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. *Molecular and cellular biology* 2008, 28(10):3457-3464.
73. Meng S, Luo M, Sun H, Yu X, Shen ML, Zhang QC, Zhou RD, Ju XF, Tao W, Liu D *et al*: Identification and Characterization of Bmi-1-responding Element within the Human p16 Promoter. *J Biol Chem* 2010, 285(43):33219-33229.
74. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Monch K, Minucci S, Porse BT, Marine JC *et al*: The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. *Genes & development* 2007, 21(5):525-530.
75. Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, Peters G, Carnero A, Beach D, Gil J: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. *Oncogene* 2005, 24(36):5543-5551.
76. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JLL, van Lohuizen M, Band V, Campisi J, Dimri GP: Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1.

- Molecular and cellular biology* 2003, 23(1):389-401.
77. Jacobs JLL, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene *bmi-1* regulates cell proliferation and senescence through the *ink4a* locus. *Nature* 1999, 397(6715):164-168.
 78. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nat Cell Biol* 1999, 1(4):193-199.
 79. Kossatz U, Malek NP: p27: tumor suppressor and oncogene ...? *Cell research* 2007, 17(10):832-833.
 80. Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. *Journal of cellular physiology* 2000, 183(1):10-17.
 81. Nickeleit I, Zender S, Kossatz U, Malek NP: p27(kip1): a target for tumor therapies? *Cell Div* 2007, 2.
 82. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, Nakayama K, Kitagawa M: Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. *J Biol Chem* 1999, 274(20):13886-13893.
 83. Kudo Y, Kitajima S, Ogawa I, Miyauchi M, Takata T: Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma. *Oral oncology* 2005, 41(2):105-116.
 84. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI: Skp2-

- mediated degradation of p27 regulates progression into mitosis. *Developmental cell* 2004, 6(5):661-672.
85. Tamamori-Adachi M, Hayashida K, Nobori K, Omizu C, Yamada K, Sakamoto N, Kamura T, Fukuda K, Ogawa S, Nakayama KI *et al*: Down-regulation of p27Kip1 promotes cell proliferation of rat neonatal cardiomyocytes induced by nuclear expression of cyclin D1 and CDK4. Evidence for impaired Skp2-dependent degradation of p27 in terminal differentiation. *J Biol Chem* 2004, 279(48):50429-50436.
86. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W: Skp2 is oncogenic and overexpressed in human cancers. *P Natl Acad Sci USA* 2001, 98(9):5043-5048.
87. Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA *et al*: WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. *Molecular cancer therapeutics* 2009, 8(2):458-468.
88. Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. *Molecular cancer* 2007, 6:24.
89. Lee SH, McCormick F: Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. *J Mol Med (Berl)* 2005, 83(4):296-307.

90. Bretones G, Acosta JC, Caraballo JM, Ferrandiz N, Gomez-Casares MT, Albajar M, Blanco R, Ruiz P, Hung WC, Albero MP *et al*: SKP2 Oncogene Is a Direct MYC Target Gene and MYC Down-regulates p27(KIP1) through SKP2 in Human Leukemia Cells. *Journal of Biological Chemistry* 2011, 286(11):9815-9825.
91. Auld CA, Fernandes KM, Morrison RF: Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia. *J Cell Physiol* 2007, 211(1):101-111.
92. Vennstrom B, Sheiness D, Zabielski J, Bishop JM: Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. *Journal of virology* 1982, 42(3):773-779.
93. Facchini LM, Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. *Faseb J* 1998, 12(9):633-651.
94. Schmidt EV: The role of c-myc in cellular growth control. *Oncogene* 1999, 18(19):2988-2996.
95. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV: An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome biology* 2003, 4(10):R69.
96. Gomez-Casares MT, Garcia-Alegria E, Lopez-Jorge CE, Ferrandiz N, Blanco R, Alvarez S, Vaque JP, Bretones G, Caraballo JM, Sanchez-Bailon

- P *et al*: MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1). *Oncogene* 2013, 32(17):2239-2246.
97. Seo C, Sohn JH, Ahn JS, Yim JH, Lee HK, Oh H: Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the Antarctic lichen *Stereocaulon alpinum*. *Bioorganic & medicinal chemistry letters* 2009, 19(10):2801-2803.
98. Huneck S: The significance of lichens and their metabolites. *Naturwissenschaften* 1999, 86(12):559-570.
99. Molnar K, Farkas E: Current results on biological activities of lichen secondary metabolites: a review. *Zeitschrift fur Naturforschung C, Journal of biosciences* 2010, 65(3-4):157-173.
100. Seo C, Yim JH, Lee HK, Park SM, Sohn JH, Oh H: Stereocalpin A, a bioactive cyclic depsipeptide from the Antarctic lichen *Stereocaulon alpinum* (vol 49, pg 29, 2008). *Tetrahedron Lett* 2008, 49(32):4804-4804.
101. Bhattarai HD, Kim T, Oh H, Yim JH: A new pseudodepsidone from the Antarctic lichen *Stereocaulon alpinum* and its antioxidant, antibacterial activity. *J Antibiot* 2013, 66(9):559-561.
102. Bhattarai HD, Kim T, Oh H, Yim JH: A new pseudodepsidone from the Antarctic lichen *Stereocaulon alpinum* and its antioxidant, antibacterial activity. *The Journal of antibiotics* 2013, 66(9):559-561.
103. Han SJ, Datta Bhattarai H, Jo D-G, Kang P-S, Kim DK, Kim IC, Kim JE,

- Kim K-S, Kim SJ, Kim TK *et al*: Pharmaceutical and food composition for preventing or treating diabetes or obesity. 2011 Jul 1:WO2012046945 A2012046942.
104. Jo S, Lee H, Kim S, Hwang EM, Park JY, Kang SS, Chung H: Inhibition of PCGF2 enhances granulocytic differentiation of acute promyelocytic leukemia cell line HL-60 via induction of HOXA7. *Biochemical and biophysical research communications* 2011, 416(1-2):86-91.
105. Chomczynski P, Sacchi N: The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nat Protoc* 2006, 1(2):581-585.
106. Bright J, Aylott M, Bate S, Geys H, Jarvis P, Saul J, Vonk R: Recommendations on the statistical analysis of the Comet assay. *Pharmaceutical statistics* 2011, 10(6):485-493.
107. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WKA, Fueyo J: Adenovirus-based strategies overcome temozolomide resistance by silencing the O-6-methylguanine-DNA methyltransferase promoter. *Cancer research* 2007, 67(24):11499-11504.
108. Tsang DP, Cheng AS: Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. *Journal of gastroenterology and hepatology* 2011, 26(1):19-27.
109. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor

- microRNAs to promote liver cancer metastasis. *Hepatology* 2012, 56(2):622-631.
110. Sicari BM, Troxell R, Salim F, Tanwir M, Takane KK, Fiaschi-Taesch N: c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein. *Endocrinology* 2012, 153(2):861-872.
111. Ott M, Litzemberger UM, Sahn F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M: Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. *Plos One* 2012, 7(10).
112. Wang JL, Wang H, Li ZZ, Wu QL, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN: c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells. *Plos One* 2008, 3(11).
113. Schiappacassi MB, Lovat F, Belletti B, Berton S, Colombatti A, Baldassarre G: p27kip1 Expression inhibits glioblastoma growth, invasion and tumor-induced neoangiogenesis. *Clinical & experimental metastasis* 2009, 26(7):922-922.
114. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. *Clinical Cancer Research* 2008, 14(10):2900-2908.
115. Zhang J, Stevens MF, Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance. *Current molecular pharmacology* 2012, 5(1):102-114.

116. Galia A, Calogero AE, Condorelli RA, Fraggetta F, La Corte C, Ridolfo F, Bosco P, Castiglione R, Salemi M: PARP-1 protein expression in glioblastoma multiforme. *Eur J Histochem* 2012, 56(1):45-48.
117. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L *et al*: MGMT gene silencing and benefit from temozolomide in glioblastoma. *The New England journal of medicine* 2005, 352(10):997-1003.
118. Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR: Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. *Clinical cancer research : an official journal of the American Association for Cancer Research* 1996, 2(4):735-741.
119. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H *et al*: The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. *Cancer research* 2008, 68(19):7742-7749.
120. Cui HJ, Ma J, Ding J, Li T, Alam G, Ding HF: Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. *J Biol Chem* 2006, 281(45):34696-34704.
121. Liu SL, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and

- malignant human mammary stem cells. *Cancer research* 2006, 66(12):6063-6071.
122. Gil J, Bernard D, Peters G: Role of polycomb group proteins in stem cell self-renewal and cancer. *DNA Cell Biol* 2005, 24(2):117-125.
123. Nakauchi H, Oguro H, Negishi M, Iwama A: Polycomb gene product Bmi-1 regulates stem cell self-renewal. *Ernst Schering Research Foundation workshop* 2005(54):85-100.
124. Raaphorst FM: Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. *Trends in immunology* 2003, 24(10):522-524.
125. Lessard J, Sauvageau G: Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. *Experimental hematology* 2003, 31(7):567-585.
126. Kranc KR, Bamforth SD, Braganca J, Norbury C, van Lohuizen M, Bhattacharya S: Transcriptional coactivator Cited2 induces Bmi1 and Me18 and controls fibroblast proliferation via Ink4a/ARF. *Molecular and cellular biology* 2003, 23(21):7658-7666.
127. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, Hamer PCDW, Marquez VE, Cloos J, Krichevsky AM *et al*: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. *Oncotarget* 2010, 1(8):710-720.
128. Fabbri M, Calin GA: Epigenetics and miRNAs in Human Cancer.

- Epigenetics and Cancer, Pt A* 2010, 70:87-99.
129. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tschlis PN, Struhl K: Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. *Molecular cell* 2010, 39(5):761-772.
130. Friedman JM, Jones PA, Liang GN: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. *Cell Cycle* 2009, 8(15):2313-2314.
131. Friedman JM, Liang GN, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou XH, Jones PA: The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2. *Cancer research* 2009, 69(6):2623-2629.
132. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. *Science* 2002, 298(5595):1039-1043.
133. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A *et al*: Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. *Cancer Cell* 2012, 21(1):121-135.
134. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. *Cancer-Am Cancer Soc* 2003, 97(3):644-648.

135. Egozi D, Shapira M, Paor G, Ben-Izhak O, Skorecki K, Hershko DD: Regulation of the cell cycle inhibitor p27 and its ubiquitin ligase Skp2 in differentiation of human embryonic stem cells. *Faseb J* 2007, 21(11):2807-2817.
136. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. *Blood* 2008, 112(10):4202-4212.
137. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, Barcia J, Guzman M, Velasco G: A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Molecular cancer therapeutics* 2011, 10(1):90-103.
138. Reardon DA, Wen PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. *Oncologist* 2006, 11(2):152-164.
139. Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S: STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression. *Mol Cancer Ther* 2012, 11(6):1289-1299.
140. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE: Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. *Cancer Res* 1991, 51(13):3367-3372.

141. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G: Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. *Glia* 2002, 40(1):44-54.
142. Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW: Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. *Molecular pharmacology* 2008, 74(2):505-516.
143. Liu L, Gerson SL: Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. *Curr Opin Investig Drugs* 2004, 5(6):623-627.
144. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. *Pharmacological reviews* 2002, 54(3):375-429.
145. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J *et al*: Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. *Molecular cancer research : MCR* 2009, 7(10):1686-1692.
146. Ivana Scovassi A, Diederich M: Modulation of poly(ADP-ribosylation) in apoptotic cells. *Biochemical pharmacology* 2004, 68(6):1041-1047.
147. Yelamos J, Farres J, Llacuna L, Ampurdanes C, Martin-Caballero J: PARP-1 and PARP-2: New players in tumour development. *American journal of*

- cancer research* 2011, 1(3):328-346.
148. Do K, Chen AP: Molecular Pathways: Targeting PARP in Cancer Treatment. *Clinical Cancer Research* 2013, 19(5):977-984.
149. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW: A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. *Nucleic acids research* 2003, 31(19):5526-5533.
150. Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G: BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. *Cell death & disease* 2012, 3:e412.
151. Huang H, Lin H, Zhang X, Li J: Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. *Oncology reports* 2012, 27(6):2050-2056.
152. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD: Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. *Oncology* 2010, 78(2):103-114.
153. Caruso C, Carcaterra M, Donato V: Role of radiotherapy for high grade gliomas management. *Journal of neurosurgical sciences* 2013, 57(2):163-169.
154. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K: The effectiveness and cost-effectiveness of carmustine

- implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. *Health Technol Assess* 2007, 11(45):iii-iv, ix-221.
155. De Fazio S, Russo E, Ammendola M, Donato Di Paola E, De Sarro G: Efficacy and safety of bevacizumab in glioblastomas. *Current medicinal chemistry* 2012, 19(7):972-981.
156. Weller M, Cloughesy T, Perry JR, Wick W: Standards of care for treatment of recurrent glioblastoma--are we there yet? *Neuro-oncology* 2013, 15(1):4-27.
157. Binda E, Visioli A, Reynolds B, Vescovi AL: Heterogeneity of cancer-initiating cells within glioblastoma. *Front Biosci (Schol Ed)* 2012, 4:1235-1248.
158. D'Alessandris QG, Montano N, Cenci T, Martini M, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R: Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. *Acta neurochirurgica* 2013, 155(1):33-40.
159. Dell'Albani P: Stem cell markers in gliomas. *Neurochemical research* 2008, 33(12):2407-2415.
160. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL *et al*: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of

glioblastoma multiforme and is associated with poor survival in patients.

The Journal of clinical investigation 2012, 122(1):253-266.

161. Zhang S, Zhang ZY: PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. *Drug Discov Today* 2007, 12(9-10):373-381.
162. Barr AJ: Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. *Future Med Chem* 2010, 2(10):1563-1576.

국문 요약

다형성아교모세포종은 중추신경계의 아교세포와 그 전구세포에서 기원하는 악성 원발성 뇌종양이다. PcG 단백질 중 BMI1, SUZ12, EZH2 등은 다양한 암종에서 과발현되어 암 억제 유전자의 발현을 억제시켜 암을 유발하는 것으로 알려져 있다. 본 논문에서는 발암 기전과 항암제 활성을 증진시킬 수 있는 두 가지 다른 접근을 통해 다형성아교모세포종의 치료를 위한 연구를 진행하였다. 첫째로 다형성아교모세포종에서 Polycomb Repressive complex 2 (PRC2)의 역할을 규명하여 뇌세포의 마스터 조절장치 (master regulator)로서 가능성을 연구하였다. 둘째로 남극 지의류인 *Stereocaulon alpinum*로부터 분리한 lobarstin이 기존의 항암제와 병행 투여 시 뇌암 치료의 효과를 상승시킬 수 있는지 그 가능성을 연구하였다. 실제 다형성아교모세포종의 세포주인 T98G에서 PRC2 유전자를 억제 하였을 때 G₁기에 성장이 멈춘 세포가 증가하고 세포의 증식이 억제되는 것을 확인 할 수 있었다. 기전을 살펴보게 되면 PRC2 억제는 MYC-SKP2 경로를 억제하여 SKP2에 의해 분해되는 CDKN1B 단백질의 안정성을 증가시켰다. 또한 동일한 세포주에 MYC 유전자를 과발현 시켰을 때 같은 기전이 조절되는 것을 확인할 수 있었다. 이러한 사실은 인체 뇌종양에서도 PRC2와 MYC의 과발현 CDKN1B의 발현 감소로 같은 양상이 나타남을 확인할

수 있었다. 한편으로는 PRC2가 항암제의 효과를 증진 시킬 수 있는지 T98G 세포를 이용한 *in vitro* 연구와 인체시료에서의 검정을 통해 고찰하고자 하였다. 실제 PRC2가 억제 된 T98G 세포주에서 항암제 민감성이 증가 하였다. 이는 PRC2 제어에 의해 Base Excision Repair (BER) 관련 유전자인 PARP1, XRCC1, Ligase3의 감소에 따른 것이다. 따라서 Temozolomide (TMZ: 표준치료제) 처리로 손상된 DNA가 회복이 억제 되어 세포 독성이 증가하는 것으로 판단된다. 마지막으로, 남극 지의류인 *Stereocaulon alpinum*로부터 분리된 lobarstin이 정상세포주보다 T98G 뇌암 세포주에서 높은 독성을 보임을 확인하였다. 또한 TMZ와 병행 처리시 세포 독성이 증가되는 것을 확인할 수 있었다. 이에 따른 설명으로 TMZ에 의해 손상된 DNA 병변을 회복하는 기전에 작용하는 것으로 확인하였고, 특히나 GBM에서 항암제 저항성에서 가장 이슈가 되고 있는 MGMT 유전자의 감소뿐 아니라 BER 관련 유전자들의 발현이 감소됨을 확인하였다. 이러한 결과들을 종합해보면 PRC2 억제는 뇌암 세포의 증식 억제와 표준항암제의 효과를 증진 시킬 수 있음을 알 수 있다. 또한 lobarstin은 TMZ 에 의해 손상된 DNA를 회복하는 두 가지 기전을 동시에 억제하여 병행치료제로서 효용 가능성을 보여 주고 있다.